Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
29 Julho 2024 - 5:30PM
Nyxoah to Release Second Quarter and
First Half 2024 Financial Results on August 6,
2024
Mont-Saint-Guibert, Belgium – July 29,
2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), today announced that the Company will release
financial results for the second quarter and first half 2024 on
Tuesday, August 6, 2024, after market close. Company management
will host a conference call to discuss financial results that day
beginning at 10:30pm CET / 4:30pm ET.
A webcast of the call will be accessible via the
Investor Relations page of the Nyxoah website or through this link:
Nyxoah's Q2 2024 earnings call webcast. For those not planning to
ask a question of management, the Company recommends listening via
the webcast.
If you plan to ask a question, please use the
following link: Nyxoah’s Q2 2024 earnings call. After registering,
an email will be sent, including dial-in details and a unique
conference call access code required to join the live call. To
ensure you are connected prior to the beginning of the call, the
Company suggests registering a minimum of 10 minutes before the
start of the call.
The archived webcast will be available for
replay shortly after the close of the call.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company's or, as appropriate,
the Company directors' or managements' current expectations
regarding the Genio® system; planned and ongoing clinical studies
of the Genio® system; the potential advantages of the Genio®
system; Nyxoah’s goals with respect to the development, regulatory
pathway and potential use of the Genio® system; the utility of
clinical data in potentially obtaining FDA approval of the Genio®
system; and the Company's results of operations, financial
condition, liquidity, performance, prospects, growth and
strategies. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that
could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, assumptions and factors could adversely
affect the outcome and financial effects of the plans and events
described herein. Additionally, these risks and uncertainties
include, but are not limited to, the risks and uncertainties set
forth in the “Risk Factors” section of the Company’s Annual Report
on Form 20-F for the year ended December 31, 2023, filed with the
Securities and Exchange Commission (“SEC”) on March 20, 2024, and
subsequent reports that the Company files with the SEC. A multitude
of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Contacts:
NyxoahDavid DeMartino, Chief
Strategy OfficerIR@nyxoah.com
For
MediaBelgium/FranceBackstage Communication – Gunther De
Backergunther@backstagecom.be
International/GermanyMC Services – Anne
Henneckeanne.hennecke@mc-services.eu
- ENGLISH_Q2 2024 Earnings Call Save-the-Date
Nyxoah (NASDAQ:NYXH)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Nyxoah (NASDAQ:NYXH)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
